This is a good update for the Company showing further validation of Eden’s encapsulation technology.įurther to the release dated 20 September 2011, Enegi announced that it has entered into a strategic partnership with Advanced Buoy Technology (ABT) to apply for offshore assets in the UK North Sea. Phytalexin is the Company that developed the technology behind the very successful Hedrin range of head-lice treatments, which has gained 40 per cent of the UK market and is now gaining share in most European markets, South America and Australia. The agrochemical and encapsulation company announced an agreement with Phytalexin Limited, under which Phytalexin has exclusive rights to Eden’s formulations and encapsulation technologies primarily for use as a head-lice product. This new validation is a further important step towards demonstrating that the Parsortix separation technology can capture any solid tumour cancers without the need for modification or dependence on cancer specific antibodies, unlike existing antibody affinity based technology. ANGLE has previously demonstrated that its Parsortix separation technology can capture cultured breast cancer, prostate cancer and lung cancer cells added to blood (spiked blood). The ability to capture colon cancer cells creates the possibility of developing an effective, non-invasive screening technique to enable the early diagnosis and monitoring of colorectal cancer. Angel is very well capitalised to take advantage of the opportunities that are presented to it.ĪNGLE, the technology commercialisation company, has reported that it has achieved another key milestone by confirming that its Parsortix cell separation device can capture colon cancer cells.
If you would like to unsubscribe, please email with “unsubscribe me”.ĭisclaimer- This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only- please refer to the disclaimer in full below.ĪBH Proposed Placing, AGL Validation for colon cancer, EDE New agreement, ENEG Strategic Partnership, EGX Unit Verification, EHP Interim results, FFA New partnering, FITB success in France and Germany, FIP Funding raised by Diurnal, HCM final results, IOM Trading Update, ITM New supply and distribution agreement, MSG raises equity, NPT Capital Reduction, NTOG Bale Creek, PLE PSD502 regulatory submission update, PGRP New contract wins, SOG Preliminary results, SUN FDA approval for product, SYM Preliminary results, TRS Acquisition of Turkish Exhibition Company, VPHA Full year results and ZCGP Trading Update.Īngel Biotechnology (LON: ABH 0.22p/£7.28m)*Īngel is seeking to raise a £1m through a placing of shares at the same price as the placing that was announced on 22 December 2011 as one of the institutional investors was not in a position to invest at the time of the December 2011 placing and other institutional investors who supported the December 2011 placing have asked to provide follow-on investments. The week ahead see the Budget, public finances data, MPC minutes and retail sales data all being announced in the UK. This week, the UK announced a fall in the rate of inflation to 3.4 per cent in February down from 3.6 per cent in January, whilst in the US new home building data dipped by 1.1 per cent between January and February and China announced a 6 per cent increase in the price of petrol. This week: ANGLE moves another degree, a key step for Milestone and new energy for Energetix.įewer volatilities in the financial markets last week with the FTSE 100 increasing by 75 points to 5,961 and the AIM All Share staying broadly flat at just over 800 points.